Will LDD rentals become a larger share of placements, and does the Alcon deal alter standalone international strategy?

Management is open to offering flexible LDD access, including rentals particularly for international expansion. The Alcon deal does not alter standalone OUS expansion plans, which remain focused on disciplined entry into high-potential markets. “I think we need to be really thoughtful about going into markets where there is real potential... that's really a unique and separate strategy than what we see with Alcon.”

Could RxSight explore non-exclusive partnership deals with other major device manufacturers?

While the Alcon arrangement is non-exclusive and leaves strategic options open long-term, current executive focus is strictly on executing the milestones and maximizing value with Alcon. “it's not exclusive... but if you ask what our focus is today, it is to maximize the value of our relationship with what a great partner today.”

Does withdrawing full-year guidance imply significant ongoing business disruption or bigger strategy changes?

Withdrawing guidance reflects a deliberate choice to enable a thorough business review without arbitrary constraints, rather than signaling current operational failure. Q3-to-date trends show improvement relative to prior quarters. “This is really about us saying, hey, look, we may need to make some more changes, and we just want to account for any disruption in the business that might happen in that acute period.”

RXST

RxSight (RXST) Q1 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q1 FY26)· Health Care· Aug 5, 2026

Source: earnings call transcript

Executive summary

RxSight, Inc. Q2 FY26 — Alcon Strategic Collaboration and Leadership Transition

RxSight reported a transformational Q2 FY26 highlighted by a major strategic partnership with Alcon that validates its postoperative light-adjustability platform. Under newly appointed CEO Aziz Motivala, the company is pivoting commercial focus toward driving deeper procedure utilization across its 1,166 LDD installed base. While core product revenue faced near-term competitive pressure from market trialing, management withdrew FY26 guidance to realign sales and commercial operations for long-term growth, supported by a fortified balance sheet.

Highlights

Secured a landmark multi-year strategic collaboration agreement with Alcon, providing $200.0M in upfront and milestone payments plus future royalties
Maintained a strong cash position ending the quarter with $209.0M in cash, cash equivalents, and short-term investments, excluding $60.0M received post-quarter
Gross margin improved to 76.7% inclusive of collaboration revenue, or 71.2% on core product sales
Expanding US LAL sales force with plans to double headcount through internal resource reallocation without increasing overall operating expenses

Concerns

Withdrew full-year 2026 financial guidance (previously revised to $140.0M-$160.0M on July 7) to allow new CEO time for business assessment, with formal guidance resuming in early 2027
Core Q2 product revenue declined 19% YoY to $27.2M due to aggressive competitive trialing and soft consumer sentiment
LAL unit volume dropped 9% YoY to 24,917 units, while LDD placements decreased to 12 units (plus 1 rental)

Guidance & targets

Category	Target	Timeline	Confidence
Alcon Collaboration Revenue Recognition	$30.0M-$40.0M high materiality	FY26 · 2026	Medium
Full-Year Financial Guidance Status	Withdrawn; resume early 2027 high materiality	FY26 · 2026	High
US Sales Force Headcount	Double current headcount over time medium materiality	Medium-term	Medium

Segment performance

Segment	Revenue	YoY	QoQ	Margin
Light Adjustable Lens (LAL) Core procedure revenue impacted by competitive trialing programs and economic pressure on premium elective procedures. LAL unit volume: 24,917 unitsLAL unit YoY growth: -9.0%Percentage of product sales: 90.1%	$24.5M	-9.3%	—	—
Light Delivery Device (LDD) Capital placements were subdued as practices evaluated competitive offerings; introduced first rental model placement. Capital LDD units sold: 12 unitsRental LDD units placed: 1 unitTotal installed base: 1,166 units	$1.3M	—	—	—
Collaboration Revenue (Alcon) Reflects the portion of the initial milestone payment allocated to licensed IP under the strategic agreement. Initial milestone allocation: $6.5M	$6.5M	—	—	—

Deals & partnerships

Alcon Development and license collaboration for light-adjustable PCIOLs $200.0M in upfront and milestone payments, plus ongoing royalties Multi-year

Non-exclusive strategic agreement combining RxSight's postoperative adjustability technology with Alcon's presbyopia-correcting IOL optics.

Risks & headwinds

Competitive Trialling Activity Expected to persist through remainder of FY26

Contributed to 19% drop in core product sales and lower LDD placements (12 units)

Mitigation:Doubling US sales force to increase account depth and educating clinicians on superior refractive precision

Consumer Sentiment and Economic Headwinds Ongoing through FY26

Unusual softness in overall cataract procedure volumes noted

Mitigation:Strengthening practice marketing support and clinical outcome registry evidence

Short-Term Strategy Disruption Next 2 quarters

Withdrawal of FY26 guidance; formal target re-establishment postponed to early 2027

Mitigation:Disciplined internal resource reallocation to fund sales expansion without inflating overall OpEx

What to watch in Q2 FY26

Alcon Collaboration Revenue Recognition

Q3 FY26 / Q4 FY26

Current $6.5M

Target Limited Q3 contribution; $30.0M-$40.0M FY26 total

Why it matters

Tracks operational milestone delivery under the transformational partnership.

We anticipate limited revenue contribution in Q3 with the balance of the $30 to $40 million recognized in Q4.

Find out whether RXST delivers this. Inve re-checks your case every morning.

Q&A highlights

What attracted you to RxSight, and what factors led to the growth deceleration and lower utilization?

Motivala highlighted LAL's unique value proposition as a category-creator in ophthalmology. Growth slowed due to pivoting from initial account acquisition (breadth) to driving account utilization (depth). Physicians reaffirm high confidence in the product, and none report reaching maximum procedure capacity.

“Nobody I've talked to said that they've capped out their ability to do LALs. They've all said they could do more.”

asked by Robbie Marcus (JP Morgan) · answered by Aziz Motivala

2 min read 5 chapters

Detailed narrative

Leadership Transition and Commercial Focus

RxSight welcomed Aziz Motivala as President and CEO, bringing extensive commercial leadership experience from Tarsus Pharmaceuticals and broader eye care sectors. Co-founder Dr. Ron Kurtz transitioned to Chief Medical Officer to maintain strong focus on clinical progress and physician relationships.

Motivala outlined core priorities including completing a full commercial assessment, doubling the US sales team via resource reallocation, sharpening forecasting discipline, and accelerating uptake of next-generation adjustable technology.

Strategic Collaboration with Alcon

The company entered into a major multi-year collaboration agreement with Alcon to co-develop postoperative light-adjustable presbyopia-correcting intraocular lenses (PCIOLs). The agreement includes $200.0M in upfront and milestone payments, along with significant long-term royalties. $6.5M of collaboration revenue was recognized in Q2 FY26 for licensed IP, and management expects $30.0M to $40.0M total recognition in FY26, primarily weighted to Q4.

Commercial Dynamics and Market Headwinds

Core product revenue during Q2 declined 19% YoY to $27.2M, driven by intense competitive product trialing, broader macroeconomic pressure on discretionary healthcare, and typical Q3 seasonality. LAL procedure volume reached 24,917 units (down 9% YoY). Placements of Light Delivery Devices (LDDs) totaled 12 sales and 1 initial rental contract, bringing the active installed base to 1,166 units.

Financial Results and Balance Sheet Strength

Total Q2 FY26 revenue reached $33.7M including $6.5M collaboration revenue. Gross margin expanded to 76.7% (71.2% excluding collaboration benefit). Non-GAAP adjusted net loss was $4.6M ($0.11 per share), excluding $7.5M in stock-based compensation. Cash, cash equivalents, and short-term investments stood at $209.0M as of June 30, 2026, which excludes $60.0M received in July post-quarter from Alcon.

Internal Pipeline Advancement

RxSight continues to advance its internal pipeline of next-generation hybrid IOL materials, including LAL, LAL+, and LAL Toric. These products aim to enhance surgical workflow, reduce required post-op light adjustments from current averages (1.5 adjustments and ~2 lock-ins down toward 1 lock-in), and broaden the addressable patient pool.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.